ClinicalTrials.gg
Active, not recruitingNCT04944043Updated Dec 3, 2025

A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease

A Phase 1/2 interventional study of TQ05105 Tablet in Chronic Graft Versus Host Disease, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Enrollment
24th of 42
45 · median 50
Started
2021
with 3 others
Phase 1/2
5 of 52
1 open now
Primary completion
2023-06
later than 0 of 24 live
Registered
24th of 52
by date
Lead sponsor
2 of 52
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 24th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 1/2, reaches primary completion later than 0 of the 24 other live ones, and was the 24th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

This study was a single arm, open label, multicenter phase Ib / II trial in subjects with glucocorticoid refractory / dependent moderate to severe cGVHD.The trial consisted of two phases: phase I for the dose exploration and phase II for the extension study.

03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understood and signed an form.
  • ≥18 years old, Performance Scale of ≥60, ≥ 6 months.
  • Has received hematopoietic stem cell transplantation (alloSCT).
  • Clinically diagnosed moderate to severe cGVHD according to NIH Consensus Criteria.
  • Has received systemic or topical therapy and confirmed steroid-/dependent cGVHD according to NIH Consensus Criteria.
  • Has received at least 1 for cGVHD.
  • Adequate laboratory indicators.
  • No pregnant or breastfeeding women, and a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Has active acute .
  • Has previously failed to respond to JAK inhibitors for GVHD, or who had used JAK inhibitors within 4 weeks before the first administration.
  • Has uncontrollable active infections or infections requiring systematic treatment within 7 days before the first administration.
  • Development of other basic diseases.
  • Has malignant tumors within 3 years.
  • Has multiple factors affecting oral medication.
  • Has substance abuse or a psychotic disorder.
  • Has severe and / or uncontrolled disease.
  • Allergic to drugs or its constituents.
  • Has participated in any other clinical trials within 4 weeks before first administration.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    TQ05105 Tablet

    TQ05105 tablet 10mg given orally, twice daily in 28-cycle.

    Drug: TQ05105 Tablet

Interventions

  • TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.

06

What researchers measure

Primary outcomes

  1. Maximal Tolerable Dose (MTD)

    If dose limiting toxicity (DLT) occurs in 2 or more subjects in a given dose group, the dose level in the previous dose group is considered MTD. (Patients in phase Ib)

    Time frame: Baseline up to 4 weeks

  2. Recommended phase II dose (RP2D)

    Recommended dose for phase II (Patients in phase Ib)

    Time frame: Baseline up to 4 weeks

  3. Best Overall Response Rate (BOR)

    Percentage of participants achieving complete response (CR) and partial response (PR). (Patients in phase II)

    Time frame: Baseline up to 96 weeks

Secondary outcomes

  1. Overall Response Rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR) during the study according to the cGVHD NIH Consensus Criteria.

    Time frame: Baseline up to 52 weeks

  2. Duration of Response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression.

    Time frame: Baseline up to 96 weeks

  3. Overall survival (OS)

    OS defined as the time from randomization to the time of death from any cause.

    Time frame: Baseline up to death event, up to 5 years.

  4. Non-relapse mortality (NRM)

    Defined as the date of first dose to the date of death from non hematologic disease recurrence / progression

    Time frame: Baseline up to 96 weeks

  5. Failure Free Survival (FFS)

    Defined as absence of relapse, death, or need for additional systemic immunosuppressant cGVHD therapy.

    Time frame: Baseline up to 12 months

  6. Changes in glucocorticoid dose

    The reduction in glucocorticoid requirement would be regarded as an effect of the trial drug.

    Time frame: Baseline up to 96 weeks

  7. Changes in symptom burden

    Evaluate changes in symptom burden as measured by the Lee Symptom Scale. A change of 7 points on the Lee Symptom Scale will be considered clinically significant and relates to improvement in quality of life.

    Time frame: Baseline up to 96 weeks

  8. Maximum plasma concentration (Cmax)

    Cmax is the maximum plasma concentration of TQ05105 or its metabolite(s).

    Time frame: Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.

  9. Time to reach maximum plasma concentration (Tmax)

    To characterize the pharmacokinetics of TQ05105 by assessment of time to reach maximum plasma concentration.

    Time frame: Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.

  10. Area under the plasma concentration time curve (AUC0-t)

    To characterize the pharmacokinetics of TQ05105 by assessment of area under the plasma concentration time curve from zero to infinity.

    Time frame: Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 1; Pre-dose of day 3,day5, day 6 ;Pre-dose, 5, 15 , 30 minutes, 1 , 2 , 3 , 6, 8, 11 hours post-dose of day 7.

  11. Incidence rate of adverse event

    The occurrence rate of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs) assessed based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: Baseline up to 96 weeks.

07

Study locations

12 sites
08

References and documents

Publications

  • Zhao YM, Luo Y, Shi JM, Wang SQ, Wang CK, Jiang EL, Liang C, Zhu XY, Zhang XJ, Meng FK, Jin H, Zhao YQ, Yu J, Lai XY, Liu LZ, Fu HR, Ye YS, Zhang CX, Wang T, Tu LF, Wang XQ, Huang H. A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD. Blood. 2025 Jun 12;145(24):2857-2872. doi: 10.1182/blood.2024026581. PubMed 40009501 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2023, 24 months.

Of 24 phase 1/2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 87. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jun 29, 2021
StartActual
Jun 25, 2021
Primary completionActual
Jun 30, 2023
CompletionEst.
Dec 31, 2026
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04944043
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
Jun 25, 2021
Primary completion
Jun 30, 2023
Completion
Dec 31, 2026 (estimated)
Last update
Dec 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion